Morphotek enters collaboration to investigate CA125 tumour antigen
3 December 2015 | By Victoria White
Morphotek has teamed up with UW-Madison to investigate the immunosuppressive effects of CA125 on farletuzumab...
List view / Grid view
3 December 2015 | By Victoria White
Morphotek has teamed up with UW-Madison to investigate the immunosuppressive effects of CA125 on farletuzumab...
18 November 2015 | By Victoria White
Morphotek and the TAT Group will investigate farletuzumab as an alpha therapy vector for radioimmunotherapy in ovarian cancer...
26 October 2015 | By Victoria White
The new findings have led to the hypothesis that patients with high levels of CA125 have an immunosuppressive tumour microenvironment that may potentially enable cancer cells to escape immune-mediated cytotoxicity...